Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

Condition:   Extranodal NK/T-cell Lymphoma Interventions:   Biological: Sugemalimab;   Drug: Placebo;   Drug: Pegaspargase;   Drug: Gemcitabine;   Drug: Oxaliplatin Sponsor:   CStone Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials